Compare AU
Compare IHOO vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P Global 100 Multi-nationals (AUD Hedged) (IHOO) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IHOO | CURE | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 83 |
Median incremental investment | $1,020.50 | $619.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $7,362.80 | $1,461.60 |
Average age group | > 35 | > 35 |
Key Summary
IHOO | CURE | |
---|---|---|
Strategy | IHOO.AX was created on 2014-12-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 478.19m in AUM and 104 holdings. The fund aims to provide investors with the performance of the S&P Global 100 Hedged AUD Index, before fees and expenses. The index is designed to measure the AUD hedged performance of 100 multi-national, blue chip companies of major importance in global equity markets | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | APPLE INC (12.53 %) NVIDIA CORP (11.90 %) MICROSOFT CORP (10.90 %) | Natera Inc (3.33 %) Incyte Corp (2.95 %) Gilead Sciences Inc (2.81 %) |
Top 3 industries | Information Technology (41.20 %) Health Care (10.04 %) Consumer Discretionary (9.13 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (81.06 %) United Kingdom of Great Britain and Northern Ireland (4.32 %) Switzerland (3.26 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.43 % | 0.45 % |
Key Summary
IHOO | CURE | |
---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P Global 100 Hedged to AUD Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.43 % | 0.45 % |
Price | $186.40 | $52.00 |
Size | $486.061 million | $36.301 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.07 % | 4.24 % |
Market | ASX | ASX |
First listed date | 18/12/2014 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IHOO | CURE | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 12 | 83 |
Median incremental investment | $1,020.50 | $619.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $7,362.80 | $1,461.60 |
Average age group | > 35 | > 35 |
Pros and Cons
IHOO | CURE | |
---|---|---|
Pros |
|
|
Cons |
|
|
IHOO | CURE |
---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |